PARCLYA
Dead / Abandoned — Abandoned — no statement of use filed (as of 13 Oct 2026)
What this means for you
This application is over — abandoned 13 Oct 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97662905
- Mark type
- Word mark
- Filed
- 05 Nov 2022
- Published for opposition
- 18 Jul 2023
- Abandoned
- 13 Oct 2026
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; all of the above excluding contraceptives
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prior registrations
Prosecution history
- 13 Oct 2026 — ABANDONMENT - NO USE STATEMENT FILED
- 13 Oct 2026 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 15 Jul 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Jul 2026 — SOU EXTENSION 5 GRANTED
- 03 Mar 2026 — SOU EXTENSION 5 FILED
- 15 Jul 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 03 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Sept 2025 — SOU EXTENSION 4 GRANTED
- 06 Sept 2025 — SOU EXTENSION 4 FILED
- 06 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Mar 2025 — SOU EXTENSION 3 GRANTED
- 10 Mar 2025 — SOU EXTENSION 3 FILED
- 10 Mar 2025 — SOU TEAS EXTENSION RECEIVED